In pancreatic ductal adenocarcinoma (PDA), AnxA2 can promote the secretion and thereby increase the levels of SEMA3D, and primary PDA patients that express high levels of SEMA3D have a wider range of metastases than those who express lower levels of SEMA3D [7]. Here, SEMA3D is linked to pancreatic ductal adenocarcinoma.